Definition And Overview
- Denotes occurrence of clinical disease in an individual despite receiving vaccination.
- Categorized into primary vaccine failure and secondary vaccine failure.
- Generally remains rare following administration of measles, diphtheria, and tetanus vaccines.
Classification And Comparative Profile
| Feature | Primary Vaccine Failure | Secondary Vaccine Failure |
|---|
| Core Definition | Inability of recommended vaccine dose(s) to induce an immune response. | Occurrence of clinical disease despite prior successful induction of immune response. |
| Pathophysiology | Complete failure of initial seroconversion or cell-mediated immunity generation. | Waning of protective immunity and immunological memory over time. |
| Common Causes | Maternal antibody interference, concomitant infections, cold chain interruptions. | Natural decline in antibody titers, inadequate generation of memory B cells. |
| Classic Examples | Oral poliovirus vaccine, Measles vaccine. | Bacillus Calmette-Guérin, Pertussis vaccine, Typhoid vaccine. |
| Management Strategy | Administer multiple primary doses or delay vaccination until maternal antibodies wane. | Administer scheduled booster doses to sustain protective antibody titers. |
Etiological Factors
Host Factors
- Residual maternal antibodies neutralize vaccine organism before infection occurs, interrupting immune response.
- Causes primary vaccine failure in 15 percent of measles vaccine recipients, making subsequent doses necessary.
- Concomitant diarrhea and competition by other enteroviruses reduce vaccine take for oral poliovirus vaccine.
- Severe congenital or acquired immunodeficiency syndrome prevents adequate immune response generation.
Vaccine And Programmatic Factors
- Interruptions in vaccine cold chain damage heat-sensitive or freeze-sensitive formulations, leading to absent immunogenicity.
- Inadequate antigen dose fails to circumvent inhibitory influence of maternal antibodies.
- Polysaccharide vaccines fail to induce germinal centers, limiting memory cell generation and causing rapid secondary failure.
Specific Clinical Scenarios
Breakthrough Varicella
- Defined as varicella illness developing greater than 42 days post-immunization.
- Manifests typically 2 to 5 years following vaccination due to waning immunity.
- Disease remains mild, exhibiting fewer than 50 maculopapular lesions, low fever, and shorter illness duration.
- Risk factors include vaccination below 15 months of age, steroid administration, and increasing time since immunization.
- Two-dose schedule effectively reduces primary vaccine failure risk and provides sustained protection against breakthrough disease.
Pertussis Vaccine
- Protective efficacy wanes significantly over 6 to 12 years following primary immunization.
- Represents classic secondary vaccine failure.
- Necessitates booster doses during childhood and adolescence to sustain protective antibody titers.
